NovoCure Q3 Earnings Call Highlights

NovoCure NASDAQ: NVCR reported third-quarter 2026 net revenue of $193 million, up 16% from a year earlier, as growth in its Optune Gio business and an expanding launch of Optune Lua in Japan helped lift active patient counts to a record level. The company also raised its full-year revenue and adjusted EBITDA outlook while acknowledging commercial headwinds for its newer Optune Pax therapy in the United States.

MarketBeat • 9 hours ago

NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript

NovoCure Limited ( NVCR ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants Adam Daney - Head of Investor Relations William Doyle - Executive Chairman Frank Leonard - CEO & Director Christoph Brackmann - Chief Financial Officer Uri Weinberg - Chief Innovation Officer & Chief Medical Officer Conference Call Participants Vijay Kumar - Evercore ISI Institutional Equities, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Jason Bednar - Piper Sandler & Co., Research Division Tanmay Patwardhan - JPMorgan Chase & Co. Kevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good day, and welcome to the NovoCure Q3 2026 Earnings Call. [Operator Instructions] Please note, this call may be recorded.

Seeking Alpha • 5 hours ago

Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) today reported financial results for the third quarter that ended September 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “Novocure's strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launchin.

Business Wire • 18 hours ago

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

NovoCure (NVCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.33 per share a year ago.

Zacks Investment Research • 16 hours ago

Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure's Tumor Treating Fields (TTFields) therapy with chemotherapy and VS-7375, Verastem's investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, to treat locally advanced pancreatic cancer. “Meaningful progress has been made in the treatment of pancreatic cancer and we are prou.

Business Wire • Oct 28, 2026

Novocure: A Mispriced Cash-Generating Biotech With Upside Potential

NovoCure is undervalued at a $1.66B market cap, with its pipeline and FDA-approved products not fully reflected in its price. NVCR's revenue grew 16% YoY to $183.58M, with international sales and patient adoption accelerating, especially for new launches like Optune Pax. Valuation multiples are below sector medians (EV/Sales 2.05x vs. 3.66x), while the pipeline and upcoming Optune Mya launch offer significant upside.

Seeking Alpha • Oct 13, 2026

Novocure to Report Third Quarter 2026 Financial Results

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 29, to discuss the company's financial results for the three-month period that ended September 30, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided.

Business Wire • Oct 1, 2026

Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel. “The approval of Optune Pax provides a promising new treatment option for locally advanced pancreatic cancer, a disease with an urgent need for effective therapies,” said Makoto Ueno, MD, PhD, D.

Business Wire • Oct 1, 2026

NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even

NovoCure NASDAQ: NVCR outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference.

MarketBeat • Sep 18, 2026

NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 14, 2026